Compare Hinge Health Inc. Class A Common Stock (HNGE) vs UBS Group AG Registered Ordinary Shares (UBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs UBS Group AG Registered Ordinary Shares — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while UBS Group AG Registered Ordinary Shares trades at $46.9 (market cap $147.14B). The key difference: UBS Group AG Registered Ordinary Shares is far larger — about 17.4× Hinge Health Inc. Class A Common Stock's market cap, and UBS Group AG Registered Ordinary Shares pays a 2.3% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and UBS Group AG Registered Ordinary Shares for 3 Days on average.
| HNGE | UBS | |
|---|---|---|
Market Cap | $8.48B | $147.14B |
Volume | 879,799 | 1,589,541 |
Sector | Health | Financials |
52-Week High | $105.14 | $55.72 |
52-Week Low | $31.17 | $36.41 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $8.10B | $315.77B |
Dividend Yield | — | 2.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
UBS trades at $47.85, showing minimal daily movement with a 0.06% gain. The technical picture is bearish with mixed earnings performance - beating estimates in Q1 2026 but missing in Q4 2025 and Q2 2026. Analyst sentiment leans positive with 55% buy ratings, though the consensus price target of $23.57 sits well below current levels. Recent news highlights UBS's strategic focus on US expansion and ongoing integration challenges.
The outlook remains cautious given the bearish technical signals and valuation concerns. Investment opportunity exists in the company's improving profitability and revenue growth trajectory, but risks include integration challenges from recent acquisitions and exposure to European debt market volatility. The significant gap between current price and analyst targets warrants careful consideration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About UBS Group AG Registered Ordinary Shares
UBS is a global financial services company focused on wealth management, investment banking, and asset management. It serves private, corporate, and institutional clients.
Read more on UBS →
